YOU ARE HERE > Home > News > Drug Value & Market Access Optimization

Drug Value & Market Access Optimization

Description

June 2016 - The "Drug Value & Market Access Optimization" report has been designed as a working tool to help pharmaceutical companies optimize the valuation of their drugs.

This report reviews:
- The economic and healthcare environment
- The R&D cost of drugs
- The drug pricing strategic approaches of pharmaceutical companies, governments and payers
- The market access processes in selected countries (France, Germany, Italy, Spain, UK and USA)
- The best practices in market access
The ways to leverage the corporate reputation of pharma companies

 

Product details

Soft copy: 200 slides (PowerPoint)
Language: English
Price: €5,000 (excl. tax)

Download short version (free)

 

 

 

 

 

Contents

1. Introduction
1.1. Foreword
1.2. International healthcare expenditure
1.3. Global Pharma market
1.4. Global Pharma R&D 
1.5. Global Pharma profitability
1.6. Global Pharma reputation 
1.7. Conclusion

2. R&D cost of drugs
2.1. Introduction
2.2. R&D processes
2.3. R&D cost estimates
2.4. Focus on biosimilars
2.5. Focus on vaccines
2.6. Conclusion

3. Drug pricing approaches
3.1. Introduction
3.2. Free pricing
3.3. Cost-based pricing
3.4. Value-based pricing
3.5. Internal price referencing
3.6. International price referencing
3.7. Managed entry agreements
3.8. Price cuts
3.9. Paybacks
3.10. Tenders
3.11. Compulsory licensing
3.12. Voluntary licensing
3.13. Tiered pricing
3.14. Other considerations
3.15. Conclusion

4. Health economic evaluations
4.1. Introduction
4.2. Generalities
4.3. Methods of health economic evaluation
4.4. Conclusion

5. Market access processes
5.1. Introduction
5.2. France
5.3. Germany
5.4. Italy
5.5. Spain
5.6. UK
5.7. USA
5.8. Conclusion

6. Best practices

7. Corporate reputation leverage

8. Conclusion & recommendations

9. Appendices